Results 61 to 70 of about 12,575 (207)

Profile of darunavir in the management of treatment-experienced HIV patients [PDF]

, 2009
Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3 ...
Cameron Wolfe, Charles Hicks
core  

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK [PDF]

, 2016
Background: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials ...
Churchill, D., Cane, P., Leigh-Brown, A., Hubb, J., Collins, S., Mitchell, S., Smit, E., Fisher, M., Aitken, C., Lewszuk, A., Weber, J., Zhang, H., Smith, C., Perry, N., Hu('e), S., Nastouli, E., Williams, I., Munshi, S., Hunter, M., Brima, N., Porter, K., Clark, D., Nelson, M., Ashton, L., Atkinson, C., de Souza, C., Fearnhill, E., Allan, S., Sabin, C. A., Youle, M., Post, F., Bradley-Stewart, A., Youssef, E., Jones, R., Shepherd, J., Carder, M., White, E., Kellam, P., Anderson, J., Dhillon, M., Campbell, L., Hale, A., Fawcett, T., Lazarus, L., Wood, C., Templeton, K., Pritchard, J., O(')Shea, S., Gunson, R., Gilson, R., Lampe, F., Douthwaite, S., Mackie, N., Ibrahim, F., Huntington, S., Jose, S., Russell-Sharpe, S., Greatorex, J., Walsh, J., Tandy, R., Kemble, C., Gravely, J., Babiker, A., Lynch, J., Mbisa, J. L., Mandalia, S., Winston, A., Hand, J., Payne, B., Garcia-Diaz, A., Kirk, S., Hopkins, M., Harte, A., Johnson, M., Fraser, C., Schwenk, A., Pozniak, A. L., Booth, C., Fairbrother, K., Hutchinson, S., Ainsworth, J., Chaloner, C., Phillips, A. N., Tariq, A., Gleisner, Z., Mbisa, T., Tsintas, R., Ramzan, F., Asboe, D., Everett, R., Cox, A., Thornton, A., Hill, T., Tilbury, S., Delpech, V., Spencer, H., Orkin, C., Sachikonye, M., Tilston, P., Pillay, D., Cumming, S., Palfreeman, A., Faleye, A., Hay, P., Kegg, S., Taylor, C., Gompels, M., Kaye, S., Adefisan, A., Clay, S., Miller, S., Wilson, A., Moses, S., Tostevin, A., Glabay, A., Leen, C., El Bouzidi, K., Sabin, C., Geretti, A. M., Mullen, J., Dunn, D. T., Gazzard, B., Baillie, K., Memon, K., Chadwick, D., Pozniak, A., Morris, S., Schmid, M. L.   +127 more
core   +4 more sources

Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates

Chemical Biology &Drug Design, Volume 107, Issue 6, June 2026.
Three decades of cruzain‐targeted drug discovery have yielded 215 sub‐micromolar inhibitors but no clinical candidates. This review diagnoses a systemic translational failure driven by single‐parameter optimisation and proposes a multiparametric framework integrating enzymatic potency, cathepsin selectivity, intracellular exposure, and metabolic ...
Caroline Rodrigues Chaves dos Reis, Hellen Valério Chaves Moura de Souza, Lidia Corrêa Parra, Guilber Valério Chaves Moura de Souza, Bruna Costa Zorzanelli, Nubia Boechat, Lucas Villas Bôas Hoelz, Tácio Vinício Amorim Fernandes   +7 more
wiley   +1 more source

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. [PDF]

, 2012
Objectives: To compare cerebrospinal fluid (CSF) darunavir and ritonavir concentrations in patients receiving darunavir/ritonavir 800/100 mg once daily or 600/100 mg twice daily.
Marinaro, L., D'Avolio, Antonio, D'Avolio, A., Bonora, S., Simiele, M., Yilmaz, Aylin,, Siccardi, Marco, Calcagno, A., Marinaro, Letizia, Simiele, Marco, Cusato, Jessica, Bertucci, R., Bonora, Stefano, Cusato, J., Calcagno, Andrea, Di Perri, G., Yilmaz A, Bertucci R, Siccardi, M., Di Perri, Giovanni   +19 more
core   +1 more source

Darunavir, Ritonavir, and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women [PDF]

, 2011
We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma for women from the G ender, R ace a nd C linical
Kristine Patterson, Patterson, Kristine, Kashuba, Angela, Joseph Mrus, Angela Kashuba, Ron Falcon, Falcon, Ron, Jennings, Steven, Mrus, Joseph, Steven Jennings   +9 more
core   +2 more sources

Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials. [PDF]

PLoS ONE, 2013
The development of tipranavir and darunavir, second generation non-peptidic HIV protease inhibitors, with marked improved resistance profiles, has opened a new perspective on the treatment of antiretroviral therapy (ART) experienced HIV patients with ...
Asres Berhan, Yifru Berhan
doaj   +1 more source

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, Volume 27, Issue 6, Page 918-934, June 2026.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.

PLoS ONE, 2022
BackgroundCoronavirus Disease 2019 (COVID-19) is an evolving pandemic that urged the need to investigate various antiviral therapies. This study was conducted to compare efficacy and safety outcomes of darunavir-cobicistat versus lopinavir-ritonavir in ...
Eman Zeyad I Elmekaty, Rim Alibrahim, Rania Hassanin, Sitelbanat Eltaib, Ahmed Elsayed, Fatima Rustom, Mohamed Izham Mohamed Ibrahim, Mohammed Abu Khattab, Hussam Al Soub, Muna Al Maslamani, Abdullatif Al-Khal   +10 more
doaj   +1 more source

Automated Near Real‐Time QC for LC‐HRMS

Rapid Communications in Mass Spectrometry, Volume 40, Issue 10, 30 May 2026.
ABSTRACT Rationale The quality of analytical measurements is typically evaluated after completion of the entire, or possibly multiple, measurement batch(es). Automated, near real‐time quality control (QC) during LC‐HRMS acquisition can prevent reruns and sample loss by flagging issues as they occur.
Michael J. Mohr, Linus Strähle, Tobias Bader, Pia Leurle, Jan H. Christensen, Wolfram Seitz, Rudi Winzenbacher   +6 more
wiley   +1 more source